Will Radius Health's Abaloparatide Data Do The Trick In Osteoporosis?
Abaloparatide looks better for improving bone mass with less hypercalcemia than Lilly's first-in-class Forteo in the Phase III ACTIVE study, but it remains to be seen whether this will be enough to get ahead in the increasingly crowded osteoporosis market.
You may also be interested in...
Tymlos Inclusion Stands Out As Express Scripts Reveals 2018 Formulary
Radius Health's pricing and reimbursement strategy has been successful, at least with Express Scripts, which included its bone-builder Tymlos on a 2018 formulary that excludes several brand-name drugs.
Radius Prices Osteoporosis 'Blockbuster' Tymlos To Compete, Grow Market
At $19,500 per year, Radius Health's Tymlos (abaloparatide) is priced to compete with Lilly's similar, but well-established drug Forteo. The company hopes to increase the size of the osteoporosis market to achieve its blockbuster sales goal, but at least one analyst has her doubts.
Keeping Track: Breakthroughs Dominate 2017 Novel Agents; US FDA Approves Rydapt, Alunbrig, Tymlos, Brineura
The latest drug development news and highlights from our FDA Performance Tracker.